Matrivax Research & Development

Matrivax is a clinical-stage biotechnology company focused on developing vaccines against major infectious diseases using its proprietary Protein Capsular Matrix Vaccine (PCMV) platform. The PCMV technology simplifies the production of conjugate vaccines by entrapping polysaccharides within a protein matrix, potentially offering a more scalable and affordable alternative to traditional conjugation methods. The company's lead candidate, MVX-01, is a 26-valent pneumococcal vaccine designed to provide broader protection than current market leaders. Matrivax is also advancing programs for Clostridioides difficile and other bacterial infections. The company is headquartered in Boston and leverages technology originally licensed from Boston Children's Hospital.